Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs.

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Research

Background:

• Recombinant tissue plasminogen activator (r-tPA) is the primary treatment for ischemic stroke.
• The narrow 3-hour therapeutic window for r-tPA limits its clinical effectiveness.
• Investigating strategies to extend the r-tPA treatment window is crucial.

Purpose of the Study:

• To evaluate the efficacy of resveratrol as an adjuvant therapy with delayed r-tPA administration.
• To determine if resveratrol improves treatment outcomes in patients receiving late r-tPA treatment.
• To explore the potential mechanisms, including matrix metalloproteinase (MMP) levels, underlying resveratrol's effect.

Main Methods:

• Patients were stratified into early or delayed onset-to-treatment time (OTT) groups.
• Treatment arms included r-tPA plus placebo or r-tPA plus resveratrol.
• Outcomes assessed included NIH stroke scale (NIHSS) and plasma MMP-2/MMP-9 levels via ELISA.

Main Results:

• Resveratrol significantly improved NIHSS scores in patients receiving delayed r-tPA treatment compared to placebo.
• Resveratrol administration led to a reduction in plasma MMP-2 and MMP-9 levels.
• A positive correlation was found between reduced MMP levels and improved NIHSS scores.

Conclusions:

• Resveratrol shows potential as an adjuvant therapy to extend the therapeutic window of r-tPA.
• This combination therapy may improve outcomes for patients treated later for ischemic stroke.
• Resveratrol's mechanism may involve the downregulation of MMPs, contributing to better neurological recovery.